1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. ExpreS2ion Biotech Holding AB (publ)
  6. Summary
    EXPRS2   SE0008348262

EXPRES2ION BIOTECH HOLDING AB (PUBL)

(EXPRS2)
  Report
Delayed Nasdaq Stockholm  -  05/20 11:29:38 am EDT
15.10 SEK   -1.76%
05/09Scientific article about the advantageous S2-based protein secretion system ExpreS2 and a moderate-throughput research variant called FAS2FURIOUS
AQ
05/05ExpreS2ion announces final outcome of fully guaranteed rights issue of approximately SEK 73 million
AQ
05/05ExpreS2ion Up 34% After Releasing Further Data From Booster Vaccine Clinical Trial
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Stockholm
05/16/2022 05/17/2022 05/18/2022 05/19/2022 05/20/2022 Date
13.86(c) 14(c) 14.23(c) 15.37(c) 15.1(c) Last
54 276 73 356 188 381 312 956 192 212 Volume
+4.76% +1.01% +1.64% +8.01% -1.76% Change
More quotes
Estimated financial data (e)
Sales 2022 12,0 M 1,21 M 1,21 M
Net income 2022 -80,0 M -8,07 M -8,07 M
Net Debt 2022 42,0 M 4,24 M 4,24 M
P/E ratio 2022 -4,11x
Yield 2022 -
Sales 2023 286 M 28,8 M 28,8 M
Net income 2023 142 M 14,3 M 14,3 M
Net cash position 2023 103 M 10,4 M 10,4 M
P/E ratio 2023 2,31x
Yield 2023 -
Capitalization 724 M 73,0 M 73,0 M
EV / Sales 2022 63,8x
EV / Sales 2023 2,17x
Nbr of Employees 26
Free-Float 87,1%
More Financials
Company
ExpreS2ion Biotech Holding AB is a Sweden-based biopharmaceutical company. The Company specializes in developing cell lines and processes based on a non-viral Drosophila S2 cells expression system. The Company's ExpreS2 recombinant protein expression platform supports all phases of drug discovery, research and development and manufacturing. ExpreS2 is a non-viral insect cell expression system that establishes stable... 
Sector
Pharmaceuticals
Calendar
05/19Earnings Release
More about the company
Ratings of ExpreS2ion Biotech Holding AB (publ)
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about EXPRES2ION BIOTECH HOLDING AB (PUBL)
05/09Scientific article about the advantageous S2-based protein secretion system ExpreS2 and..
AQ
05/05ExpreS2ion announces final outcome of fully guaranteed rights issue of approximately SE..
AQ
05/05ExpreS2ion Up 34% After Releasing Further Data From Booster Vaccine Clinical Trial
MT
05/05Positive Omicron data from the COVID-19 Phase II trial reported for the ABNCoV2 vaccine
AQ
05/05Expres2ion Biotech Holding AB Announces Positive Omicron Data from the Covid-19 Phase I..
CI
05/04ExpreS2ion - Annual report for 2021 published
AQ
04/25EXPRES2ION BIOTECH : Proxy Form
PU
04/25EXPRES2ION BIOTECH : Notification and form for advance voting
PU
04/25EXPRES2ION BIOTECH : Bilingual version where the Swedish text prevails
PU
04/25Notice of Annual General Meeting in ExpreS2ion Biotech Holding AB
AQ
04/21BIOSTOCK STUDIO : Expres2ion's CEO gives status update
AQ
04/20ExpreS2ion publishes video presentation
AQ
04/19Frontiers in Immunology publishes article about ABNCoV2
AQ
04/19BIOSTOCK INVESTOR PITCH : ExpreS2ion Biotechnologies
AQ
04/13ExpreS2ion publishes prospectus in connection with fully guaranteed rights issue of app..
AQ
More news
News in other languages on EXPRES2ION BIOTECH HOLDING AB (PUBL)
05/05Expres2ion Biotech Holding AB (Publ) annonce des données omicroniques positives issues ..
02/28Expres2ion Biotech Holding AB (Publ) fournit des résultats positifs supplémentaires de ..
02/24ExpreS2ion Biotech Holding AB (publ) annonce ses résultats pour le quatrième trimestre ..
02/24ExpreS2ion Biotech Holding AB (publ) annonce ses résultats pour l'exercice clos le 31 d..
2021ExpreS2ion Biotech Holding AB nomme Mattis F. Ranthe au poste de médecin en chef, à com..
More news
Chart EXPRES2ION BIOTECH HOLDING AB (PUBL)
Duration : Period :
ExpreS2ion Biotech Holding AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXPRES2ION BIOTECH HOLDING AB (PUBL)
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 15,37 SEK
Average target price 86,00 SEK
Spread / Average Target 460%
EPS Revisions
Managers and Directors
Bent U. Frandsen Chief Executive Officer
Keith Alexander Chief Financial Officer
Martin Roland Jensen Chairman
Max M. Søgaard Vice President-Technology, Research & Development
Mette Thorn Vice President-Preclinical Development
Sector and Competitors